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was a Zaire subtype that differed from the original
1976 strain in four bases (<1%). No differences were
seen when the polymerase gene PCR products (~350
bp) from those four patients were sequenced, which
indicated that they had been infected with the same
virus. Three days later, sequence data from ex-
panded analysis of the entire glycoprotein gene were
compared with those of the original 1976 Yambuku
isolate (9) and showed that the overall difference
between these Ebola viruses was less than 1.6%.
Such little change in viruses that caused outbreaks
of disease at extreme ends of Zaire separated by a
span of nearly 19 years, may indicate that the
genomes of Ebola viruses (and filoviruses in general)
are unusually stable and have evolved to occupy
special niches in the wild.
The capability to rapidly diagnose and charac-
terize filovirus infections is critical to the ability of
public health professionals to identify and limit the
spread of future outbreaks of filovirus disease. A
continued commitment to research and modern dis-
ease-surveillance programs is necessary to minimize
or preclude filovirus outbreaks similar to that in
Kikwit. The possibility of outbreaks is increasingly
likely given the continued human incursions into the
African forests and the vulnerability of large impov-
erished populations to rapid transmission of disease
as a result of inadequate public health services. With
the current outbreak under control, CDC and col-
laborators have begun their efforts to identify the
natural reservoir by sending teams of scientists to
collect specimens from the area where the putative
index patient worked. Attempts to identify the res-
ervoir after outbreaks in 1976 and 1979 were handi-
capped by the lack of satisfactory diagnostic tools
that are critical to detecting small quantities of the
virus. However, now that sensitive enzyme immu-
noassays and PCR assays have been developed for
filoviruses, the chances are much better that, if ap-
propriate materials can be collected in the field, the
virus can be detected.
In conclusion, we want to alert physicians and
public health agencies who encounter persons that
have clinical signs and symptoms of hemorrhagic
fever disease to the reemergence of Ebola virus.
Recommendations for the management of viral hem-
orrhagic fevers attributable to filoviruses in the
United States were recently published in CDC’s Mor-
bidity and Mortality Weekly Report (1995;44:475-79).
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Prospects for the Control of Bolivian
Hemorrhagic Fever
Bolivian hemorrhagic fever (BHF) was first iden-
tified in 1959 as a sporadic hemorrhagic illness in
rural areas of Beni department, Bolivia. Clusters of
BHF patients were noted the same year, and by 1962
BHF was recognized as a new epidemic infectious
disease. In 1963, Machupo virus (a member of the
family Arenaviridae) was first isolated from patients
with acute hemorrhagic fever in San Joaquin, Bo-
livia (1). Ecologic investigations established the ro-
dent Calomys callosus, which is indigenous to the
disease-endemic region of northern Bolivia, as the
reservoir for Machupo virus (2,3).
Machupo virus infection in C. callosus results in
asymptomatic infection with shedding of virus in
saliva, urine, and feces; 50% of experimentally in-
fected C. callosus are chronically viremic and shed
virus in their bodily excretions or secretions (2).
Although the infectious dose of Machupo virus in
humans is unknown, exposed persons may become
infected by inhaling virus shed in aerosolized secre-
tions or excretions of infected rodents, by eating food
contaminated with rodent excreta, or by direct con-
tact of excreta with abraded skin or oropharyngeal
mucous membranes (4). Reports of person-to-person
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tact with a patient resulted in person-to-person
spread of Machupo virus to nursing and pathology
laboratory staff (5). In 1994, the fatal secondary
infection of six family members in Magdalena from
a single naturally acquired infection further sug-
gested the potential for person-to-person transmis-
sion (Ksiazek et al., manuscript in preparation).
The pathogenesis of BHF, which resembles that of
other South American hemorrhagic fevers due to
Arenavirus infection (e.g., Argentine hemorrhagic
fever), has been described in clinical and pathologic
investigations of naturally infected patients (6,7).
Experimental infection of rhesus monkeys with
Machupo virus demonstrated an incubation period
of 7 to 14 days, which is consistent with clinical
observations in human infection (8). Early clinical
manifestations in humans are characterized by non-
specific signs and symptoms including fever, head-
ache, fatigue, myalgia, and arthralgia. Later in the
course of disease (usually within 7 days of onset),
patients may develop hemorrhagic signs, including
bleeding from the oral and nasal mucosa and from
the bronchopulmonary, gastrointestinal, and geni-
tourinary tracts.
During the BHF epidemics in the 1960s, rodent
control was recognized as the primary method for the
prevention of Machupo virus transmission (9). Since
C. callosus was frequently found in domestic and
peridomestic environments, rodent control meas-
ures (e.g., trapping, poisoning) resulted in an imme-
diate reduction in the number of C. callosus and
control of BHF outbreaks; an epidemic in 1964 ended
after 2 weeks of continuous trapping for C. callosus
in homes of the affected community (10). Rodent
control programs became a new priority for health
officials in Bolivia, and active interventional pro-
grams were carried out for many years by survivors
of past BHF epidemics known to be immune to
Machupo virus (11).
 From 1973 to 1992, no cases of BHF were re-
ported, possibly because of effective control of rodent
reservoir populations (12). Since the late 1960s, no
epidemics of BHF have occurred that involve rural
communities, but recent sporadic cases have been
identified in the disease-endemic region (13). Al-
though patients with BHF have been treated at
hospitals outside the disease-endemic region, these
patients had a history of exposure to Machupo virus
in the disease-endemic region or secondary contact
with BHF patients who became infected in the en-
demic region. Additionally, no documented cases of
BHF have been exported to other countries.
Concurrently with the lack of identification of
BHF patients during the 1970s and 1980s, the em-
phasis on conducting rodent control programs in the
BHF-endemic areas also diminished. Moreover, in
recent years, Bolivian health officials have been
faced with numerous other public health problems,
including diarrheal disease, tuberculosis, Chagas’
disease, sexually transmitted diseases, and acquired
immunodeficiency syndrome. Thus, local health
authorities are confronted with the challenge of allo-
cating limited health resources for the control of
BHF as the demand for work with other important
diseases increases.
Agricultural activities dominate the economy of
northern Bolivia where many workers are employed
in farming and animal husbandry (14). Farm work-
ers may reside for prolonged periods in rural areas
also inhabited by C. callosus, and farm houses con-
structed with partially open walls may allow rodents
access to living areas. Thus, human exposure to
infected rodents may occur in and around farm work-
ers’ shelters or during work in the fields and grass-
lands of the BHF-endemic region. Given the
projected economic growth in Bolivia, it is likely that
agricultural workers’ risk for exposure to C. callosus
will continue and even increase as development
modifies the natural habitat of the rodent reservoir
leading to increased contact with humans (e.g., fo-
cused rodent habitats with increased densities) (15).
Future efforts to control BHF may benefit from
recent experience in neighboring Argentina where
ongoing work has led to the control of Argentine
hemorrhagic fever (AHF), caused by Junin virus, an
arenavirus genetically related to Machupo virus.
Extensive study of AHF by Maiztegui, Enria, and
colleagues has provided new insights into the
epidemiology, pathogenesis, treatment, and control
of this disease (16,17) and has led to an effective
Candid #1 vaccine against Junin virus as well as
phase 2 clinical trials that suggest ribavirin may be
effective in patients with AHF (18,19). The use of an
effective vaccine against AHF and evidence for its
cross-protection against Machupo virus suggest that
vaccination may play a role in the prevention of BHF
for persons at highest risk, such as workers who trap
rodents for control programs (20). Intravenous
ribavirin has shown promise for the treatment of
clinically diagnosed BHF cases subsequently con-
firmed in the laboratory (Kilgore, manuscript in
preparation). Intravenous ribavirin also appeared
effective in the treatment of a laboratory-acquired
infection with Sabiá virus, a related Arenavirus first
isolated in Brazil (21). Ribavirin could be adminis-
tered to patients whose symptoms meet a clinical
case definition with subsequent laboratory confirma-
tion of Machupo virus infection. Local laboratory
handling of specimens or testing by effective rapid
enzyme-linked immunosorbent assays for antigen
and IgM antibodies is ideally performed under
biosafety level 4 containment, but use of biological
safety cabinets and addition to samples of inexpen-
sive reagents such as Triton X-100, which reduce
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real time testing.
The family cluster of BHF patients and later
sporadic cases in September and October 1994 high-
lighted the diagnostic challenge of BHF for clini-
cians. Even local physicians may rarely evaluate
BHF patients, and other diseases (e.g., malaria, den-
gue fever, and yellow fever) that coexist in the BHF-
endemic region may resemble BHF in the early
phases of illness. Moreover, no readily available di-
agnostic tests exist locally to differentiate BHF from
other diseases (22). Bolivian health care providers
and public health officials recognized the need for
education of health care providers and subsequently
established a training program aimed at increasing
clinicians’ recognition of BHF particularly in the
disease-endemic region.
The cluster of patients in 1994 also focused public
attention on BHF because the illnesses had higher
case-fatality rate than other diseases in the region
where BHF is endemic. The underrecognition of
these illnesses as dangerous and potentially fatal in
disease-endemic communities suggests the need for
increased public health education to reduce virus
exposure and transmission. Proven control meas-
ures must be reinforced even in towns affected by
large epidemics 30 years ago where younger resi-
dents have no recollection of the heavy toll exacted
by BHF. Prevention of communitywide epidemics
through rodent control programs may be combined
with the application of barrier precautions (e.g.,
gloves, masks) in hospitals or clinics to minimize
secondary person-to-person transmission of
Machupo virus. After the familial cluster of BHF in
1994, results of rodent trapping confirmed the ab-
sence of reinfestation in towns and indicated that the
density of rodent reservoirs was not unusually high
in areas of probable exposure for the index patient.
The absence of communitywide epidemics of BHF
suggests that focused rodent control in towns of the
disease-endemic region prevented large urban out-
breaks. Prevention of sporadic illness in farm work-
ers through widespread elimination of reservoirs
may not be feasible, but other measures, such as the
administration of Candid #1 AHF vaccine to workers
at high risk, may offer a more realistic alternative.
Finally, agricultural workers in the disease-endemic
region should be taught methods to reduce exposure
to rodent reservoirs, especially around rural shelters
as a means of reducing their risk of exposure to
Machupo virus in the environment.
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